Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results

SAN DIEGO - 
      ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company 
      utilizing innovative technology to fuel drug discovery and clinical 
      development of novel treatments for central nervous system disorders, 
      today reported its unaudited financial results for the third quarter
Posted : Mon, 09 Nov 2009 21:10:54 GMT
Author : ACADIA Pharmaceuticals Inc.
Category : Press Release
News Alerts by Email ( click here )
Press Release News | Home
SAN DIEGO - (Business Wire) ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2009.

ACADIA reported a net loss of $8.7 million, or $0.23 per common share, for the third quarter of 2009 compared to a net loss of $15.6 million, or $0.42 per common share, for the third quarter of 2008. For the nine months ended September 30, 2009, ACADIA reported a net loss of $36.5 million, or $0.98 per common share, compared to a net loss of $50.3 million, or $1.36 per common share, for the comparable period of 2008.

At September 30, 2009, ACADIA’s cash, cash equivalents, and investment securities totaled $54.9 million compared to $60.1 million at December 31, 2008.

“The cost saving measures that we recently have undertaken extended our cash runway through 2011 and have positioned ACADIA to continue to pursue its portfolio of product candidates that provide multiple clinical and commercial opportunities,” said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. “While we were disappointed with the results of the first Phase III trial in Parkinson’s disease psychosis announced during the third quarter, we remain enthusiastic about the broad development strategy we are pursuing together with Biovail, which provides the opportunity to fully explore the clinical and commercial potential of pimavanserin over three different neurological and psychiatric indications with large unmet medical needs.”

Revenues increased to $2.4 million for the third quarter of 2009 from $282,000 for the third quarter of 2008. This increase was primarily due to $1.9 million in revenues recognized under ACADIA’s collaboration with Biovail, which commenced in May 2009, as well as increased revenues from other agreements.

Research and development expenses decreased to $9.2 million for the third quarter of 2009, including $280,000 in stock-based compensation, from $13.4 million for the third quarter of 2008, including $346,000 in stock-based compensation. The decrease in research and development expenses was primarily due to $3.6 million in decreased personnel and other costs associated with ACADIA’s research and development organization following a restructuring in August 2008, and lower external service costs. External service costs totaled $6.1 million for the third quarter of 2009, compared to $6.6 million for the third quarter of 2008, and were primarily comprised of development costs for pimavanserin.

General and administrative expenses decreased to $2.0 million for the third quarter of 2009, including $331,000 in stock-based compensation, from $3.0 million for the third quarter of 2008, including $446,000 in stock-based compensation. The decrease in general and administrative expenses was primarily due to $813,000 in decreased personnel costs, and lower external service costs.

In October 2009, ACADIA implemented a restructuring to further streamline its operations, reduce its internal operating expenses, and extend its cash runway. Following these cost saving measures, ACADIA currently anticipates that its cash, cash equivalents and investment securities will be in the range of $43 to $45 million at December 31, 2009, and that the Company’s existing cash resources and anticipated payments from its collaborations will be sufficient to fund its operations through the end of 2011.

Conference Call and Webcast Information

ACADIA management will review its third quarter results and development programs via conference call and webcast today at 5:00 p.m. Eastern Time. The conference call may be accessed by dialing 866-510-0707 for participants in the U.S. or Canada and 617-597-5376 for international callers (reference passcode 92783090). A telephone replay of the conference call may be accessed through November 23, 2009 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 21130876). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there until November 23, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA’s product candidates include pimavanserin in Phase III development for Parkinson’s disease psychosis in collaboration with Biovail, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and AM-831 in IND-track development in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA’s pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs either alone or with a partner, including clinical trials and the results therefrom, and the benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin, potential payments under its collaboration agreements, its future cash position and the length of its cash runway. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and collaborations with others, and the fact that past results of clinical trials may not be indicative of further trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2008 as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(Unaudited)

       

Three Months Ended
September 30,

Nine Months Ended
September 30,

2009

   

2008

2009

   

2008

 
 
Collaborative revenues $ 2,435 $ 282 $ 4,630 $ 1,265
 
Operating expenses
Research and development (includes stock-based compensation of $280, $346, $784 and $1,141, respectively) 9,215 13,397 33,749 44,604
General and administrative (includes stock-based compensation of $331, $446, $1,018 and $1,298, respectively)   1,994     2,974     7,643     9,428  
Total operating expenses   11,209     16,371     41,392     54,032  
Loss from operations (8,774 ) (16,089 ) (36,762 ) (52,767 )
Interest income (expense), net   46     475     306     2,486  
Net loss $ (8,728 ) $ (15,614 ) $ (36,456 ) $ (50,281 )
Net loss per common share, basic and diluted $ (0.23 ) $ (0.42 ) $ (0.98 ) $ (1.36 )
Weighted average common shares outstanding, basic and diluted   37,383     37,137     37,262     37,098  

ACADIA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(Unaudited)

       

September 30,

2009

December 31,

2008(1)

 
Assets
Cash, cash equivalents, and investment securities $ 54,909 $ 60,083
Prepaid expenses, receivables and other current assets   1,895   2,299
Total current assets 56,804 62,382
Property and equipment, net 1,498 2,103
Other assets   173   192
Total assets $ 58,475 $ 64,677
Liabilities and Stockholders’ Equity
Current liabilities 15,248 11,051
Long-term liabilities 24,260 634
Stockholders’ equity   18,967   52,992
Total liabilities and stockholders’ equity $ 58,475 $ 64,677
 

(1) The condensed consolidated balance sheet at December 31, 2008 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Vice President and Chief Financial Officer
858-558-2871


Copyright © 2008 Business Wire. All rights reserved.
Share/Save/Bookmark

Article : ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News

REMINDER: Media Advisory: LAX FlyAway(R) Service Formally Inaugurates Daily Nonstop Bus Service to Irvine, Six Times Daily
LOS ANGELES, CA -- 11/22/09 -- WHAT: Los Angeles Mayor Antonio R. Villaraigosa will be joined by officials from the City of Irvine and Orange County transportation agencies to formally inaugurate the ne..

Maxprog Releases New MaxBulk Mailer 7
Maxprog is proud to present a new release of MaxBulk Mailer, new version 7, available now on Maxprog website with several interesting new features and improvements. MaxBulk Mailer is an email-merge solution for Macintosh and Windows that supports plain text, HTML and rich text formats includi...

Andean Resources Ltd.: New San Marcos Discovery at Cerro Negro
PERTH, AUSTRALIA -- 11/22/09 -- Andean Resources (TSX: AND)(ASX: AND) is pleased to report another new vein discovery from the ongoing exploration drill program at its 100% owned Cerro Negro project in Southern Argentina. Today's release includes t..

Defence Minister Declares Security Forum "World-Class" Event
HALIFAX, NOVA SCOTIA -- 11/22/09 -- As the three-day Halifax International Security Forum today wrapped up its final sessions, the Honourable Peter MacKay, Minister of National Defence and Minister for the Atlantic Gateway, declared the inaugural e..

Radiance Fine Jewelry 3rd Annual Holiday Party and Galatea Trunk Show
CHICAGO, IL -- 11/22/09 -- With the coming holidays, why give the same gift that everyone else is giving when you can come by Radiance Fine Jewelry and get something truly special. "Galatea Jewelry by Artist" has created some of the most unique pie..

The Grove’s Annual Tree Lighting Celebration and Concert, Sponsored by Cadillac, Features Special Performances, Celebrity Appearances, Lighting of the 100-ft Tree and Spectacular Fireworks Finale
LOS ANGELES - The Grove will host its annual tree-lighting event, “Hollywood Christmas Celebration at The Grove” on Sunday, November 22 at 7:30 p.m. The festive celebration, free to the public, draws crowds from throughout Los Angeles who come to see the stunning 100-foot Christm

Doctors Day Announces Exclusive Miniature Stethoscope Lapel Pin for Doctor Gift and Nurse Gift
The National Doctors' Day organization today announced the introduction of its miniature stethoscope lapel pin. At only 3/4 inches in height, it is the first realistic stethoscope lapel pin that is small enough to truly be considered a lapel pin. Unique gifts for doctors are difficult to fin...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.